Program Description & Educational Objectives

In this activity, experts in the management of non–small-cell lung cancer (NSCLC) utilize a clinical case scenario to discuss practical aspects of the use of tumor histology and mutational analysis as guides for treatment selection in the front-line, maintenance, and second-line therapy settings and beyond. Recent data on available and emerging therapies for the treatment of NSCLC are also reviewed.

Upon completion of this activity, participants should be better able to:

• Select appropriate personalized front-line therapy for a patient with advanced NSCLC based on the results of pathologic and molecular testing
• Identify clinical settings appropriate for maintenance therapy in metastatic NSCLC, and appropriately administer validated maintenance strategies for eligible patients
• Consider personalized therapy for a patient with advanced NSCLC who progresses after upfront treatment or for a pretreated individual who has failed more than one prior line of therapy

Target Audience

This activity has been designed to meet the educational needs of medical oncologists and other clinicians involved in the management of non–small-cell lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: November 23, 2011 - November 22, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of New Mexico Health Sciences Center, School of Medicine, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. The relationships were reviewed by UNM CME and conflicts of interest were resolved prior to the activity.

Course Director and Interviewee

Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Corey J. Langer, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc. [Roche]; GlaxoSmithKline; ImClone Systems Incorporated; OSI Pharmaceuticals, Inc.; and Pfizer Inc.
Advisory Board for (Scientific Advisor) Abraxis Oncology [Celgene]; Abbott Laboratories; Amgen Inc.; ARIAD Pharmaceuticals, Inc.; AstraZeneca; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Biodesix; Bristol-Myers Squibb; Boehringer Ingelheim; Caris Life Sciences, Inc.; Clarient, Inc.; Eli Lilly and Company; ImClone Systems Incorporated; Genentech, Inc. [Roche]; Morphotek Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis; and Synta Pharmaceuticals Corp.

Interviewee

Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
University of Pittsburgh
Director, Lung Cancer Section, Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Celgene Corporation; Eli Lilly and Company; Genentech, Inc.; Pfizer Inc.; and Synta Pharmaceuticals Corp.
Speakers Bureau participant with Eli Lilly and Company; and Genentech, Inc.

CME Reviewer

Julie Bauman, MD, MPH
Assistant Professor
Department of Internal Medicine, Division of Hematology/Oncology
University of New Mexico Health Sciences Center School of Medicine
Albuquerque, New Mexico

Julie Bauman, MD, MPH, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of New Mexico Health Sciences Center, School of Medicine and PVI, PeerView Institute for Medical Education. The University of New Mexico Health Sciences Center, School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of New Mexico Health Sciences Center, School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by the University of New Mexico Health Sciences Center, School of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.